Get in touch +44 (0) 1638 720 500 
Latest news
Quotient Bioresearch extends agreement with GE Healthcare to complete transfer into new radiochemistry facility in Cardiff
18 January 2010, Cambridgeshire, UK: An extension to the manufacturing transfer agreement that was put in place with GE Healthcare (GEHC) as part of the Quotient Bioresearch acquisition of Amersham Radiolabelling Services, the custom radiochemical synthesis operations of GE Healthcare, has now been agreed. This extension will assure customers of a smooth transition and uninterrupted supply of carbon-14 labelled compounds during the move of Amersham Radiolabelling Services from the existing site to its new state-of-the-art facility in Cardiff this Spring.
COPD white paper kick-starts new information programme from Quotient Bioresearch
Cambridgeshire, UK, 24 November 2009: The latest addition to Quotient Bioresearch’s ongoing ‘Evidence’ information series is now available for download. Biomarkers in Respiratory Disease – Part 1: Chronic Obstructive Pulmonary Disease (COPD) is the first white paper in a new series that will explore the value that biomarkers can add to drug discovery and development in important therapeutic areas.
Quotient Clinical Demonstrates Effective Drug Product Optimisation with RapidFACT Platform
Cambridgeshire, UK, 26th October 2009 – Quotient Clinical, a strategic business unit of leading drug development services provider Quotient Bioresearch (“Quotient”), today announces the availability of a new white paper demonstrating the advanced capabilities of the novel RapidFACT™ approach: an integrated formulation development, manufacture and clinical testing service. RapidFACT can be used to optimise drug products with significantly shorter timelines and reduced associated expenditure compared to traditional approaches.